Alberto J. Espay

Alberto J. Espay's AcademicInfluence.com Rankings

Alberto J. Espay

Medical

#2971

World Rank

#3418

Historical Rank

Neurology

#282

World Rank

#362

Historical Rank

medical Degrees

Download Badge

Medical

Alberto J. Espay's Degrees

PhD Clinical Research University of Cincinnati

Why Is Alberto J. Espay Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alberto J. Espay's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (2014) (524)
Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke (2002) (479)
Technology in Parkinson's disease: Challenges and opportunities (2016) (411)
Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders (2018) (347)
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. (2006) (297)
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations (2018) (237)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease (2015) (223)
A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy (2014) (214)
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. (2014) (205)
Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results (2014) (187)
“On” state freezing of gait in Parkinson disease (2012) (181)
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts (2018) (177)
APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. (2014) (175)
Cortical and spinal abnormalities in psychogenic dystonia (2006) (173)
Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement (2014) (166)
A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies (2019) (161)
The modified bradykinesia rating scale for Parkinson's disease: Reliability and comparison with kinematic measures (2011) (159)
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease (2016) (157)
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial (2013) (156)
Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members (2009) (154)
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases (2019) (146)
At-home training with closed-loop augmented-reality cueing device for improving gait in patients with Parkinson disease. (2010) (128)
Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease. (2014) (127)
Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials (2017) (127)
Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research (2012) (126)
Precision medicine for disease modification in Parkinson disease (2017) (125)
Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration (2017) (121)
Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease (2011) (121)
Interhemispheric and ipsilateral connections in Parkinson's disease: Relation to mirror movements (2007) (108)
Feasibility of home-based automated Parkinson's disease motor assessment (2012) (107)
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease (2017) (105)
Phenotype-Specific Diagnosis of Functional (Psychogenic) Movement Disorders (2015) (102)
Autonomic dysfunction in Parkinson's disease: A prospective cohort study (2018) (98)
Mirror movements in parkinsonism: evaluation of a new clinical sign (2005) (98)
Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study (2009) (96)
Rigidity and spasms from autoimmune encephalomyelopathies: Stiff‐person syndrome (2006) (96)
Placebo effect of medication cost in Parkinson disease (2015) (94)
Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets (2016) (92)
Vascular Parkinsonism: Deconstructing a Syndrome (2015) (88)
Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials (2015) (86)
Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. (2015) (86)
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. (2013) (83)
Psychogenic Facial Movement Disorders: Clinical Features and Associated Conditions (2012) (82)
The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease (2015) (81)
Disease modification and biomarker development in Parkinson disease (2020) (74)
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how (2020) (74)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
Mutations in ZBTB20 cause Primrose syndrome (2014) (70)
Movement disorders on YouTube--caveat spectator. (2011) (69)
Methylphenidate for gait impairment in Parkinson disease (2011) (67)
Essential pitfalls in “essential” tremor (2017) (67)
Subthalamic nucleus‐deep brain stimulation for early motor complications in Parkinson's disease—the EARLYSTIM trial: Early is not always better (2014) (66)
Treatable inherited rare movement disorders (2018) (66)
Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: Preliminary observations (2008) (66)
‘Under pressure’: is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies? (2016) (66)
Telemedicine in Neurological Disorders: Opportunities and Challenges. (2019) (64)
Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic? (2016) (62)
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. (2013) (61)
Tics and functional tic-like movements (2019) (61)
Psychiatric associations of adult-onset focal dystonia phenotypes (2017) (60)
Mirror Movements in Movement Disorders: A Review (2012) (60)
Diagnostic agreement in patients with psychogenic movement disorders (2012) (59)
Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study (2017) (59)
Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders. (2020) (58)
The epileptic and nonepileptic spectrum of paroxysmal dyskinesias: Channelopathies, synaptopathies, and transportopathies (2017) (55)
Functional neurological disorders in Parkinson disease (2018) (55)
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study (2019) (55)
Cognitive profile of LRRK2‐related Parkinson's disease (2015) (55)
Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies (2019) (54)
Evaluation of mild cognitive impairment subtypes in Parkinson's disease (2014) (53)
Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. (2018) (53)
Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. (2017) (52)
Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease (2016) (51)
Parkinsonism and Frontotemporal Dementia: The Clinical Overlap (2011) (50)
Neuroimaging in Functional Neurological Disorder: State of the Field and Research Agenda (2021) (49)
Outcome measurement in functional neurological disorder: a systematic review and recommendations (2020) (49)
Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: A decision analysis (2010) (49)
Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease (2018) (48)
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. (2021) (47)
Post-stroke Movement Disorders: The Clinical, Neuroanatomic, and Demographic Portrait of 284 Published Cases. (2018) (47)
Neurologic complications of electrolyte disturbances and acid-base balance. (2014) (47)
A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson’s Disease (2016) (46)
Dysfunction in emotion processing underlies functional (psychogenic) dystonia (2018) (44)
Hallucinations, somatic‐functional disorders of PD‐DLB as expressions of thalamic dysfunction (2019) (43)
Congress of Neurological Surgeons Systematic Review and Evidence‐Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summary (2018) (43)
Clinical and neural responses to cognitive behavioral therapy for functional tremor (2019) (43)
Parkinson Disease: An Evolutionary Perspective (2017) (39)
A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein (2018) (39)
Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease (2019) (38)
The Parkinson's disease e‐diary: Developing a clinical and research tool for the digital age (2019) (38)
High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis (2021) (38)
Cognition among individuals along a spectrum of increased risk for Parkinson’s disease (2018) (38)
Consensus for the measurement of the camptocormia angle in the standing patient. (2018) (38)
Tremor retrainment as therapeutic strategy in psychogenic (functional) tremor. (2014) (37)
A writing device improves writing in primary writing tremor (2005) (36)
Long-duration Parkinson's disease: role of lateralization of motor features. (2013) (36)
Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia (2007) (35)
Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study (2019) (35)
Clinical Parkinson disease subtyping does not predict pathology (2019) (35)
Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis (2020) (35)
Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease. (2018) (35)
Advanced therapies in Parkinson's disease: Long-term retrospective study. (2016) (35)
Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease (2012) (35)
Congenital mirror movements (2014) (34)
Orthostatic hypotension in Parkinson disease: Impact on health care utilization. (2017) (33)
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease (2020) (32)
Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects (2018) (32)
Anti-N-methyl-D-aspartate receptor encephalitis: characteristic behavioral and movement disorder. (2010) (32)
Lower-body parkinsonism: reconsidering the threshold for external lumbar drainage (2008) (31)
Hydrocephalic Parkinsonism: lessons from normal pressure hydrocephalus mimics (2014) (31)
Advance care planning in Parkinson’s disease: ethical challenges and future directions (2019) (31)
Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations (2021) (31)
Surgical treatment of Parkinson disease: past, present, and future. (2013) (30)
Clinical and demographic characteristics related to onset site and spread of cervical dystonia (2016) (30)
The Final Nail in the Coffin of Disease Modification for Dopaminergic Therapies: The LEAP Trial. (2019) (30)
Postencephalitic parkinsonism and basal ganglia necrosis due to Epstein-Barr virus infection (2011) (30)
Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype (2016) (30)
What is “essential” about essential tremor? A diagnostic placeholder (2018) (29)
Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. (2018) (29)
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications (2018) (28)
Computer‐Guided Deep Brain Stimulation Programming for Parkinson's Disease (2016) (28)
Chronic isolated hemifacial spasm as a manifestation of epilepsia partialis continua (2008) (28)
The power in numbers: Gut microbiota in Parkinson's disease (2015) (27)
Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) (27)
Diagnostic Performance of the “Huffing and Puffing” Sign in Functional (Psychogenic) Movement Disorders (2015) (27)
A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia (2016) (27)
Anti-Hu-associated paraneoplastic limbic encephalitis presenting as rapidly progressive non-convulsive status epilepticus (2006) (26)
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults (2020) (26)
Technology-based assessment of motor and nonmotor phenomena in Parkinson disease (2018) (26)
Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade (2020) (26)
FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION (2007) (26)
Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research. (2019) (26)
Small intestinal bacterial overgrowth in Parkinson's disease: Tribulations of a trial. (2018) (25)
Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease (2020) (25)
Which patients with epilepsy are at risk for psychogenic nonepileptic seizures (PNES)? A multicenter case–control study (2016) (25)
Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease (2017) (25)
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial (2019) (25)
Dystonia in atypical parkinsonian disorders. (2019) (24)
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study (2006) (24)
Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry (2017) (24)
Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence (2018) (24)
Atypical Motor and Behavioral Presentations of Alzheimer Disease: A Case-based Approach (2012) (24)
ADCY5–Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder (2019) (24)
Petrositis in Ramsay Hunt syndrome with multiple cranial neuropathies. (2005) (23)
Thalamic deep brain stimulation for orthostatic tremor: A multicenter international registry (2017) (23)
Psychogenic Movement Disorders (2013) (23)
Nutritional ketosis for mild cognitive impairment in Parkinson's disease: A controlled pilot trial (2019) (23)
The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? (2020) (23)
Digital Health Revolution: Is it Time for Affordable Remote Monitoring for Parkinson’s Disease? (2015) (23)
GBA variants in REM sleep behavior disorder: a multicenter study (2019) (23)
Head tremor at disease onset: an ataxic phenotype of cervical dystonia (2019) (23)
Isolated diaphragmatic tremor (2007) (22)
Peripheral neuropathy as marker of severe Parkinson's disease phenotype (2017) (22)
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary (2021) (22)
Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus (2020) (22)
Feasibility and utility of a clinician dashboard from wearable and mobile application Parkinson’s disease data (2019) (22)
Functional dystonia. (2016) (21)
Biometric Digital Health Technology for Measuring Motor Function in Parkinson’s Disease: Results from a Feasibility and Patient Satisfaction Study (2017) (21)
Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study (2020) (21)
Images in clinical medicine. Hemichorea–hemiballism after diabetic ketoacidosis. (2010) (20)
Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis. (2019) (20)
Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications (2020) (20)
Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin (2003) (19)
Dilated Virchow–Robin spaces and parkinsonism (2013) (19)
GBA variants in REM sleep behavior disorder (2020) (19)
Parkinsonism associated with striatal perivascular space dilation (2007) (19)
24‐Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease (2016) (19)
MOTOR TICS, STEREOTYPIES, AND SELF-FLAGELLATION IN PRIMROSE SYNDROME (2010) (18)
OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review (2015) (18)
Atypical absences and recurrent absence status in an adult with Angelman syndrome due to the UBE3A mutation. (2005) (18)
Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. (2021) (18)
Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale. (2018) (18)
Parkinsonism–hyperpyrexia syndrome and deep brain stimulation (2015) (17)
Management of motor complications in Parkinson disease: current and emerging therapies. (2010) (17)
Quality of life in isolated dystonia: non-motor manifestations matter (2021) (17)
Prevalence and burden of dysautonomia in advanced Parkinson's disease (2017) (17)
The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes (2021) (17)
Soft signs in movement disorders: friends or foes? (2018) (16)
Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease (2010) (16)
Teaching NeuroImage: Oculomasticatory myorhythmia (2008) (16)
Mirror movements in Parkinson’s disease: effect of dopaminergic drugs (2006) (16)
Recurrence in Pituitary Adenomas in Childhood and Adolescence (2001) (16)
Orthostatic hypotension and dementia incidence: links and implications (2019) (15)
Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures (2020) (15)
App-Based Bradykinesia Tasks for Clinic and Home Assessment in Parkinson's Disease: Reliability and Responsiveness. (2017) (15)
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102 (2018) (14)
When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis (2020) (14)
Diagnosing and treating neurogenic orthostatic hypotension in primary care (2015) (14)
Optimizing extended-release carbidopa/levodopa in Parkinson disease (2017) (14)
Surgical treatment of movement disorders. (2006) (13)
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP) (2020) (13)
Movement disorders in non-encephalopathic Hashimoto's thyroiditis. (2018) (13)
Clinical signs in functional (psychogenic) gait disorders: a brief survey (2016) (13)
Soluble Amyloid-β Consumption in Alzheimer's Disease. (2021) (13)
Tablet-Based Application for Objective Measurement of Motor Fluctuations in Parkinson Disease (2018) (13)
Botulinum toxin type A for Levodopa‐induced cervical dyskinesias in Parkinson's disease: Unfavorable risk‐benefit ratio (2011) (13)
Multidisciplinary rehabilitation in Parkinson's disease: A milestone with future challenges (2015) (13)
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study (2021) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
The psychogenic toe signs (2011) (12)
Movement disorders research in 2021: cracking the paradigm (2022) (11)
Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis (2018) (11)
The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease. (2019) (11)
Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension (2020) (11)
Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential (2020) (11)
Remote delivery of cognitive behavioral therapy to patients with functional neurological disorders: Promise and challenges (2021) (11)
Neural activity in functional movement disorders after inpatient rehabilitation (2020) (11)
Should neurologists diagnose and manage functional neurologic disorders? It is complicated (2019) (11)
Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease (2020) (10)
Diagnostic performance of the "Huffing and Puffing" sign in psychogenic (functional) movement disorders. (2015) (10)
Movement Disorders in Prionopathies: A Systematic Review (2019) (10)
Long duration response in Parkinson's disease: levodopa revisited. (2020) (10)
Parkinson disease in Gaucher disease (2017) (10)
Non‐Motor Fluctuations in Parkinson's Disease: Validation of the Non‐Motor Fluctuation Assessment Questionnaire (2021) (10)
OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial. (2019) (10)
Variants in the Niemann–Pick type C gene NPC1 are not associated with Parkinson's disease (2020) (10)
Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD) (2020) (9)
Movement Disorders in Metabolic Disorders (2019) (9)
Hiding in Plain Sight: Functional Neurological Disorders in the News. (2019) (9)
Impaired Saccade Adaptation in Tremor-Dominant Cervical Dystonia—Evidence for Maladaptive Cerebellum (2020) (9)
Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user’s guide (2016) (9)
Diagnosis and Treatment of Functional (Psychogenic) Parkinsonism (2017) (9)
Current Guidelines for Classifying and Diagnosing Cervical Dystonia: Empirical Evidence and Recommendations (2021) (9)
The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C (2019) (9)
Pure Autonomic Failure Versus Prodromal Dysautonomia in Parkinson's Disease: Insights from the Bedside (2017) (9)
Functional movement disorders in neurogeriatric inpatients (2019) (8)
Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion (2006) (8)
Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome (2016) (8)
Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies (2022) (8)
A rare cervical dystonia mimic in adults: congenital muscular torticollis (fibromatosis colli) (2013) (8)
Cognitive fluctuations in Parkinson’s disease dementia: blood pressure lability as an underlying mechanism (2018) (8)
Future of Neurologic Examination in Clinical Practice. (2018) (8)
Dopamine dysregulation syndrome with psychosis in 24-hour intestinal levodopa infusion for Parkinson's disease. (2016) (8)
Episodic coma in a new leukodystrophy. (2002) (7)
Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders (2021) (7)
Globular Glial Tauopathy May be Mistaken for Corticobasal Syndrome—Pointers for the Clinician (2018) (7)
Skin Cancer May Delay Onset but Not Progression of Parkinson's Disease: A Nested Case-Control Study (2020) (7)
Primrose syndrome: Characterization of the phenotype in 42 patients (2020) (7)
High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations (2022) (7)
Nosography of the “essential” (2013) (7)
Writing Orthotic Device for the Management of Writer’s Cramp (2013) (7)
Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation (2017) (7)
The Parkinson Care Advocate: Integrating Care Delivery (2017) (7)
Functional neurological disorder and somatic symptom disorder in Parkinson's disease (2021) (7)
Abandoning the Proteinopathy Paradigm in Parkinson Disease. (2022) (7)
Teaching Video NeuroImages: Faciobrachial dystonic seizures (2016) (6)
Américo Negrette and Huntington's disease. (2011) (6)
Teaching Video NeuroImages: Slow periodic myoclonus in subacute sclerosing panencephalitis and fulminant Wilson disease (2019) (6)
Teaching Video NeuroImages: The underrecognized diphasic dyskinesia of Parkinson disease (2017) (6)
Neuropathic Tremor in Chronic Inflammatory Demyelinating Polyneuropathy: The Acquired Equivalent of the Roussy‐Levy Syndrome (2016) (6)
Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson's disease (2016) (6)
The odyssey of complex neurogenetic disorders: From undetermined to positive (2020) (6)
Arm Levitation as Initial Manifestation of Creutzfeldt–Jakob Disease: Case Report and Review of the Literature (2018) (6)
Primary writing tremor and writer’s cramp: Distinct phenomenology, diverging pathophysiology (2011) (6)
Ethnic Differences Between Hispanics and Non-Hispanic Whites in Neuropsychiatric Symptoms Predict Conversion to Mild Cognitive Impairment (2020) (6)
Congenital mirror movements in Parkinson's disease: Clinical and neurophysiological observations (2010) (6)
Genetic parkinsonisms and cancer: a systematic review and meta-analysis (2020) (6)
Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD) (2020) (5)
Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease (2021) (5)
Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease (2019) (5)
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism (2021) (5)
Functional tremor (2022) (5)
A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments (2022) (5)
Motor excess during movement: Overflow, mirroring, and synkinesis (2010) (5)
Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. (2019) (5)
Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology (2021) (5)
The pharmacological basis of Parkinson’s disease therapy: An overview (2016) (5)
Sensory feedback in Parkinson's disease patients with “on”-predominant freezing of gait (2013) (5)
A Multi‐center Genome‐wide Association Study of Cervical Dystonia (2021) (5)
Cerebellar limb tremor and inferior olivary hypertrophy (2006) (5)
How have advances in genetic technology modified movement disorder nosology? (2020) (5)
Movement disorders phenomenology in focal motor seizures. (2019) (5)
Thalamic Deep Brain Stimulation for tremor: The critical role of intraoperative testing. (2020) (4)
Pelvic Floor Health in Women with Parkinson's Disease. (2021) (4)
Movement disorders associated with neuronal antibodies: a data-driven approach (2022) (4)
Uncovering Essential Tremor Genetics: The Promise of Long-Read Sequencing (2022) (4)
Tremor-Dominant Cervical Dystonia: a Cerebellar Syndrome (2020) (4)
Clinical and Demographic Characteristics of Upper Limb Dystonia (2020) (4)
Parkinson's Disease: Current and Future Therapeutics and Clinical Trials (2016) (4)
Teaching Video NeuroImages: Spastic ataxia syndrome (2017) (4)
Recognizing Atypical Dopa-Responsive Dystonia and Its Mimics (2021) (4)
Development and Validation of the Orthostatic Tremor Severity and Disability Scale (OT‐10) (2020) (4)
Brain Fables (2020) (4)
Practical neurology visual review (2013) (4)
The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis. (2017) (4)
Cinnamon in a mouse model of PD (2014) (4)
Reply to: “Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus” (2021) (3)
An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer's Disease. (2022) (3)
Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodies. (2020) (3)
Progressive Ataxia with Hemiplegic Migraines: a Phenotype of CACNA1A Missense Mutations, Not CAG Repeat Expansions (2020) (3)
A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: Functional and health-related quality-of-life endpoints (2013) (3)
Juvenile levodopa‐responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment (2010) (3)
Is there even such a thing as “idiopathic normal pressure hydrocephalus”? (2017) (3)
REVERSIBLE PARKINSONISM AND ATAXIA ASSOCIATED WITH HIGH-DOSE OCTREOTIDE (2008) (3)
ADS-5102 provided reduction in motor complications in Parkinson’s disease patients with levodopa-induced dyskinesia switched from amantadine IR: Subgroup analysis from open-label study (ease LID 2) (2017) (3)
Wearable Sensors For Quantifying Deep Brain Stimulation Washout Effects On Gait In Parkinson’s Disease (P7.042) (2014) (3)
What the VaP? The meaning of "vascular parkinsonism". (2021) (3)
Levodopa and Parkinson Disease-Myths Revisited-Reply. (2017) (3)
Kinematic but not clinical measures predict falls in Parkinson-related orthostatic hypotension (2020) (3)
SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF (2022) (3)
Rhythmical Involuntary Movements (Tremor and Tremor-Like Conditions) (2016) (3)
Cautionary optimism: caffeine and Parkinson’s disease risk (2016) (3)
Myoclonus (2013) (3)
Are smartphones and machine learning enough to diagnose tremor? (2022) (3)
Arm Levitation as Initial Manifestation of Creutzfeldt–Jakob Disease: Case Report and Review of the Literature (2018) (3)
Will Artificial Intelligence Replace the Movement Disorders Specialist for Diagnosing and Managing Parkinson’s Disease? (2021) (3)
The six gaps in the search of neuroprotection for Parkinson’s disease (2012) (3)
Amaurotic and ophthalmoplegic presentation of Balint syndrome (2014) (2)
Biphasic (Subtherapeutic) Levodopa-Induced Respiratory Dysfunction in Parkinson Disease. (2021) (2)
Abnormalities of Muscle Tone (2016) (2)
Brain activation of Parkinson’s patients during a delayed cued finger movement task – a preliminary study (2008) (2)
Holmes Tremor‐Like Phenotype in DYT1 Dystonia (2018) (2)
Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF-episodes in subjects with Parkinson’s disease: preliminary results from the Phase-3 study dose titration phase (2018) (2)
Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulation (2018) (2)
Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease (2010) (2)
Unvoluntary Motor Behaviours (2016) (2)
Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial (2022) (2)
The Phenomenology of Movement Disorders (2017) (2)
Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in subjects with Parkinson’s disease: preliminary results from the Phase-3 study dose-titration phase (2018) (2)
Is Pathology Always the Diagnostic Gold Standard in Neurodegeneration? (2022) (2)
Title The RAB 39 B p . G 192 R mutation causes X-linked dominant Parkinson ' s disease Permalink (2015) (2)
Perioral and tongue fasciculations in Kennedy’s disease (2018) (2)
Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase (P1.017) (2017) (2)
Timing matters: Otological symptoms and Parkinson's disease. (2021) (2)
Toward e‐Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales (2020) (2)
Management of autonomic dysfunction in Parkinson's disease (2016) (2)
Thalamic deep brain stimulation and gait in orthostatic tremor (2017) (2)
Teaching NeuroImages: The dentate sign in subacute cerebellar ataxia (2020) (2)
Intra- and Multi-Day Home-Based Monitoring of Parkinson's Disease Motor Symptoms (P06.090) (2012) (2)
Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease. (2021) (2)
Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease (2016) (2)
ANCHOR-CD (AbobotulinumtoxinA Neurotoxin: Clinical and Health Economics Outcomes Registry in Cervical Dystonia): A Multicenter, Observational Study of Dysport in Cervical Dystonia: Baseline Data and Cycle One Efficacy Data (P7.063) (2014) (2)
Movement Disorders Clinical Practice-Case Reports Holmes tremor-like phenotype in DYT1 dystonia (2018) (1)
β‐Blocker–Induced Tremor (2021) (1)
Safety and Efficacy of Continuous Apomorphine Infusion in Patients with Parkinson's disease: Results from a Phase 3, Open-label Study (2020) (1)
Efficacy of ND0612 for nocturnal problems and early morning OFF: A blinded rater study of 2 dosing regimens (P2.8-052) (2019) (1)
Lessons and challenges of trials involving ancillary therapies for the management of Parkinson's disease (2016) (1)
Axial Disorders of Movement (2016) (1)
Hypermobile Ehlers‐Danlos Syndrome: A Prodromal Subtype of Functional Movement Disorders? (2022) (1)
Functional neurological features in Parkinson disease: a multicenter case-control study (2017) (1)
Internal Versus External Frame of Reference in Functional Movement Disorders. (2019) (1)
Your After-Visit Summary—May 29, 2042 (2022) (1)
Interim Results from an International, Open-Label Study of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson's Disease: Efficacy Analyses by Subgroups (P01.060) (2013) (1)
The Pseudodystonia of Paroxysmal Sympathetic Hyperactivity: A Reversible Post‐Anoxic Complication (2020) (1)
A novel DCC mutation and genetic heterogeneity in congenital mirror movements (2011) (1)
Detection of a-Synuclein in Saliva : The Importance of Preanalytical Assessment (2017) (1)
Commentary for “Opsoclonus myoclonus syndrome associated with GQ1b antibodies” (2012) (1)
Commentary for “Chediak‐Higashi syndrome presenting as young‐onset levodopa‐responsive parkinsonism” (2013) (1)
Double-Blind, Double-Dummy, Randomized Study of Continuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease (1)
The “broken wishbone” splenial sign: A diagnostic hallmark for SPG54 spastic ataxia (2019) (1)
Teaching Video NeuroImages: Semiology and localization of ballistic movements (2014) (1)
Functional imaging markers as outcome measures in clinical trials for Parkinson's disease (2016) (1)
Teaching Video NeuroImages: The signs of dystonic tremor (2018) (1)
Anticholinergic agents in the management of Parkinson's disease (2016) (1)
Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis (2022) (1)
Does the Anti‐Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes (2021) (1)
Runny nose sign: Sequential rhinorrhea and syncope in dementia with Lewy bodies. (2016) (1)
Subthalamic or red nucleus? A puzzling question arising during intraoperative recording for DBS (2017) (1)
Management of sleep disorders in Parkinson's disease (2016) (1)
Reply to: “Autonomic dysfunction in Parkinson's disease: The hidden game changer?” (2018) (1)
Improving anxiety in Parkinson's disease: A cautionary tale about mobile health technologies. (2020) (1)
Test-Retest Reliability of a Parkinson's Disease Monitoring System (S03.003) (2013) (1)
A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: safety and motor-symptom endpoints (2013) (1)
Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases (2020) (1)
Donanemab in Early Alzheimer's Disease. (2021) (1)
ANCHOR‐CD (AbobotulinumtoxinA Neurotoxin: Clinical and Health Economics Outcomes Registry in Cervical Dystonia): A Multicenter, Observational Study of Dysport® (AbobotulinumtoxinA) in Cervical Dystonia: Baseline Data and Cycle One Efficacy Data (2013) (1)
Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension. (2022) (1)
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia (2020) (1)
Clinical Reasoning: Importance of clinical phenomenology in the era of genetic testing (2018) (1)
Functional Movement Disorders and Deep Brain Stimulation: A Multi‐Center Study (2022) (1)
Vermian Hypoplasia and Arrested Cerebral Myelination in Two Sisters: Variant of Joubert's Syndrome or a New Syndrome? (2003) (1)
Response to: Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinson's disease. (2016) (1)
Misleading Imaging and Clinical Features in Pathology‐Proven Corticobasal Degeneration (2016) (1)
Of Synuclein and Other Demons. (2021) (1)
Association of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's Disease (2020) (1)
The allure and pitfalls of the prion-like aggregation in neurodegeneration. (2023) (0)
Can People with Normal Pressure Hydrocephalus Exercise? (2018) (0)
Deep-brain stimulation of the subthalamic nucleus in the management of Parkinson's disease (2016) (0)
Reply to ‘Neuropathological progression of clinical Parkinson disease subtypes’ (2019) (0)
Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease (2016) (0)
75. Cervical dystonia (2015) (0)
A Vasculopathic Man With “Vascular Parkinsonism” Without Vasculopathy: My Humbling Case of Normal Pressure Hydrocephalus (2012) (0)
Speed and Amplitude of Movement in Patients with Parkinson's Disease (2009) (0)
Long-term Safety and Efficacy of IPX203 in Parkinson’s Disease Patients with Motor Fluctuations: A 9-Month Open-label Extension Trial (S32.006) (2023) (0)
Selected abstracts from the 21st International Congress (2017) (0)
Prevention and management of levodopa-related motor complications (2013) (0)
The pharmacodynamics of placebo (2018) (0)
Stiff-arm syndrome (2015) (0)
Models of precision medicine for neurodegeneration. (2023) (0)
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. (2023) (0)
Patient Compliance with Parkinson's Disease Home Monitoring System (P02.244) (2012) (0)
Something Does Not Look Right (2020) (0)
Inconsistency and incongruence: the two diagnostic pillars of functional movement disorder (2022) (0)
GBA variants in REM sleep behavior disorder risk and conversion: a multicenter study (2020) (0)
Frontal Lobe Disorders (2014) (0)
The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C (2019) (0)
Alzheimer's disease: a history revisited Karl Herrup How (2022) (0)
P6.8 Congenital mirror movements and Parkinson's disease: a previously unreported association (2011) (0)
2.254 INTERIM RESULTS FROM ONGOING, LONG-TERM, OPEN-LABEL STUDY OF LEVODOPA/CARBIDOPA INTESTINAL GEL IN PATIENTS WITH PARKINSON'S DISEASE AND SEVERE MOTOR FLUCTUATIONS (2012) (0)
Management of pain and neuromuscular complications in Parkinson's disease (2016) (0)
Safety and Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion for Parkinson’s disease: Three-Year Data from the Open-Label BeyoND study (PL4.003) (2023) (0)
Books Received (2012) (0)
274 METHYLPHENIDATE FOR THE TREATMENT OF GAIT IMPAIRMENT IN PARKINSON'S DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY (PRELIMINARY RESULTS) (2010) (0)
“Memory Is So Good She Will Never Get Dementia” (2020) (0)
Short communication Anti-Hu-associated paraneoplastic limbic encephalitis presenting as rapidly progressive non-convulsive status epilepticus (2006) (0)
Diagnostic agreement is not satisfactory in psychogenic movement disorders (2010) (0)
Error in Abstract. (2017) (0)
Digital biomarkers in Parkinson's disease: missing the forest for the trees? (2023) (0)
You Have Been Diagnosed with Alzheimer Disease; Is That It? (2020) (0)
Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease (2016) (0)
Title Common variant rs 356182 near SNCA defines a Parkinson ' s disease endophenotype (2016) (0)
Look below the Surface (EEG) (2020) (0)
“The Thing about Remembering Names of Things” (2020) (0)
Talking about Family Matters (2020) (0)
Frontotemporal dementia and parkinsonism linked to chromosome 17 granulin: Clinical and pathologic study of a patient from a new pedigree (2015) (0)
Neurologic Differential Diagnosis: Mutism (2014) (0)
Disease-modifying vs symptomatic treatments: Splitting over lumping. (2023) (0)
AbobotulinumtoxinA Injection Patterns in Patients with Cervical Dystonia from the ANCHOR-CD Registry Study (P1.028) (2016) (0)
The shift to a proteinopenia paradigm in neurodegeneration. (2023) (0)
Commentary: Atypical, Early‐Onset Dystonia‐Parkinsonism with Oculogyric Crises and Anterior Horn Cell Disorder due to a Novel DJ‐1 Mutation (2021) (0)
Myoclonus Alberto J. Espay, MD, MSc, FAAN; Robert Chen, MA, MBBChir, MSc, FRCPC (2013) (0)
“That Is Not How I Feel” (2020) (0)
Difficulty with Language: When Is It Not Aphasia? (2020) (0)
SOD1-Related Cerebellar Ataxia and Motor Neuron Disease: Cp Variant as Functional Modifier? (2023) (0)
Does Head Tremor Predict Postural Instability After Bilateral Thalamic Stimulation in Essential Tremor? (2022) (0)
Evaluation of the Clinical Outcomes and Disease Burden in Advanced Parkinson’s Disease Patients: PROSPECT Study Preliminary Results (P10-11.009) (2023) (0)
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease? (2022) (0)
Sequencing the entire exome of REM sleep behavior and progression to neurodegenerative diseases (2020) (0)
Author response. (2015) (0)
Oral dopamine agonists in the management of Parkinson's disease (2016) (0)
Coxa saltans misdiagnosed as functional gait disorder (2018) (0)
The Hypothesis That Refuses to Die (2020) (0)
Predictive modeling of spread in adult‐onset isolated dystonia: Key properties and effect of tremor inclusion (2021) (0)
Lack of Organization or Coordination of Voluntary Muscle Activity (2016) (0)
Interim results from an international , open-label study of levodopa-carbidopa intestinal gel in patients with advanced Parkinson ’ s disease : efficacy results by country (2012) (0)
Redefining Bradykinesia (2023) (0)
ESPAY, Alberto: Ohio/USA (2019) (0)
Monoamine oxidase inhibitors in the management of Parkinson's disease (2016) (0)
Pseudoatrophic Pattern in Hydrocephalus (2020) (0)
Ribosomal s15: A novel therapeutic target for Parkinson's disease (2014) (0)
It’s Just Old Age (2020) (0)
Bridging knowledge gaps in movement disorders (2012) (0)
Q&A with Alberto Espay (2018) (0)
The theoretical problems of "prodrome" and "phenoconversion" in neurodegeneration. (2023) (0)
P1.135 Automated Parkinson's disease motor assessment for clinical and ambulatory monitoring (2009) (0)
Comment on: "Point of view: Wearable systems for at-home monitoring of motor complications in Parkinson's disease should deliver clinically actionable information". (2021) (0)
Acute Effects of Whole-Body Vibration at 3 , 6 , and 9 Hz on Balance and Gait in Patients with Parkinson ’ s Disease (2011) (0)
P2.134 Differential response of bradykinesia and hypokinesia to levodopa in Parkinson's disease (2009) (0)
The existential essentialism in tremor nosology –7 Pitfalls, 2 Remedies, and a Path Ahead (2022) (0)
Cognitive Decline Is Only Part of the Story (2020) (0)
Initiating pharmacotherapy in early Parkinson's disease (2020) (0)
Disease Subtypes: The Promise and the Fallacy (2020) (0)
Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
Poster 296 AbobotulinumtoxinA Injection Patterns in Patients with Cervical Dystonia from the ANCHOR‐CD Registry Study (2016) (0)
Walking Out of the Psychogenic “Bizarre-Gait” Pigeonhole: A Lesson From the Psychiatry Ward (2012) (0)
Refractory “VGKC Encephalopathy” (2020) (0)
Alzheimer’s Disease: The Case for a Paradigm Shift (2022) (0)
Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration. (2023) (0)
NDT_A_182123 2181..2194 (2019) (0)
Familial Brain Calcifications With Leukoencephalopathy (2022) (0)
A Pause in the Clause (2020) (0)
Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration. (2023) (0)
Teaching Video NeuroImages: Cluster Breathing in Brainstem-Sparing Bihemispheric Cerebral and Cerebellar Lesions (2020) (0)
“I Have Snored All My Life and It Never Affected My Work” (2020) (0)
Updated long-term safety from ongoing phase 3 trials of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease (2016) (0)
Impaired Motor Preparation in Parkinson's Patients During A Delayed Cued Finger Movement Task (2009) (0)
Faciobrachial dystonic seizures: pathognomonic phenomenology (P1.015) (2016) (0)
“This Is Not Like Him” (2020) (0)
Is There Vascular Parkinsonism? (2019) (0)
Epileptic chorea: Another window into neural networks? (2018) (0)
Non-Motor Fluctuations in Parkinson's Disease (PD): Development and Validation of the Non-Motor Fluctuation Assessment Instrument (NoMoFA) (2020) (0)
Finding gaps and building bridges in movement disorders (2012) (0)
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism (2021) (0)
Rapid Intermittent Involuntary Movements (2016) (0)
It’s Not Alzheimer Disease; Now What? (2020) (0)
Dystonia, Chorea, and Ataxia: Three Challenging Cases (2022) (0)
Recognizing the Right Signs of Memory Impairment (2020) (0)
Does a Positive Amyloid Scan Always Mean Alzheimer Disease? (2020) (0)
Management of cognitive impairment in Parkinson's disease (2016) (0)
1.252 AMÉRICO NEGRETTE AND HUNTINGTON'S DISEASE (2012) (0)
Corticobasal: The Syndrome versus the Pathology (2020) (0)
Common Pitfalls in Cognitive and Behavioral Neurology (2020) (0)
Progressive Ataxia with Hemiplegic Migraines: a Phenotype of CACNA1A Missense Mutations, Not CAG Repeat Expansions (2020) (0)
Spectrum of Pediatric to Early Adulthood POLR3A‐Associated Movement Disorders (2022) (0)
A Cervical Dystonia Mimic: Congenital Muscular Torticollis (Fibromatosis Colli) in Adulthood (P01.242) (2012) (0)
Classification and measurement of speed and amplitude impairments in patients with Parkinson's disease : a pilot study (2005) (0)
Conditions Associated with On‐State Freezing of Gait (2022) (0)
sCJD with Negative 14–3–3? (2020) (0)
Comprar Common Movement Disorders Pitfalls + Cd-Rom | Alberto J Espay | 9780521147965 | Cambridge University Press (2012) (0)
Chapter 46 – Disorders of Movement (2016) (0)
A neurobehavioralist approach to the management of cognitive impairment in Parkinson's disease (2016) (0)
Parkinsonism, Ataxia, and Cognitive Impairment after Radiation Therapy (2020) (0)
The Disease Has Caught Up with Her (2020) (0)
Role of clinical nurse educators (CNEs) in levodopa-carbidopa intestinal gel (LCIG) clinical studies in Parkinson’s disease (PD) (P6.379) (2016) (0)
Lessons and challenges of trials for other nonmotor complications of Parkinson's disease (2016) (0)
Remembering That We Forget versus Forgetting Altogether (2020) (0)
Issue Information (2022) (0)
The Stroke of Clarity (2020) (0)
Management of treatment-related behavioral disturbances in Parkinson's disease (2016) (0)
Common Movement Disorders Pitfalls: Case-Based Learning (2012) (0)
Gaps, Controversies, and Proposed Roadmap for Research in Poststroke Movement Disorders (2022) (0)
‘Hand mechanogram’ in epilepsia partialis continua (2021) (0)
Will crystal Parkin help in understanding the future of Parkinson's disease? (2015) (0)
Emerging targets and other stimulationrelated procedures in the management of Parkinson's disease (2016) (0)
Frontal, Parietal, or Neither? (2020) (0)
Effort‐Related Behaviors in Charcot's Lectures on Hysteria (2015) (0)
Experimental pharmacological agents in the management of Parkinson's disease (2016) (0)
Cognitive Impairment as an Unexpected Guest (2020) (0)
Recommendations for Virtual Administration of the PSP Rating Scale (2022) (0)
Advance care planning in Parkinson’s disease: ethical challenges and future directions (2019) (0)
Subtyping monogenic disorders: Huntington disease. (2023) (0)
Controversy: midstage vs advanced-stage deep-brain stimulation in the management of Parkinson's disease (2016) (0)
“I Have Been Taking the Same Medications for Years” (2020) (0)
“I Keep Repeating Things to Him” (2020) (0)
Comparison of methodology, patient characteristics, and treatment results from ANCHOR-CD (abobotulinumtoxinA neurotoxin: Clinical and health economics outcomes registry in cervical Dystonia) and other registry studies of botulinum toxin type A in cervical Dystonia (2016) (0)
Uncommon Causes of Movement Disorders: Psychogenic movement disorders (2011) (0)
I Don’t Know When to Stop (2020) (0)
Psychostimulants and movement disorders (2015) (0)
Lessons learned: symptomatic trials in early Parkinson's disease (2016) (0)
Flamenco dancer posture (2016) (0)
Methodologies, Patient Characteristics, and Treatment Results Between Registry Studies of Botulinum Toxin Type A in Cervical Dystonia (P1.035) (2016) (0)
Tremor-Dominant Cervical Dystonia: a Cerebellar Syndrome (2020) (0)
Disease severity does not predict effective ON-turning dose of apomorphine sublingual film (APL-130277) in patient with Parkinson’s disease (P1.023) (2017) (0)
Patterned or Repetitive Movements and/or Abnormal Posturing (2016) (0)
Thanks to Editorial Board of Arquivos de Neuro-Psiquiatria (2022) (0)
Hypokinetic (Non-Parkinsonian) Movement Disorders (2016) (0)
Calibrated use of deception in assessing the placebo effect (2018) (0)
More information 1 Missing the diagnosis altogether Case 1 : Bizarre ataxia of rapid onset (2012) (0)
Herpes Encephalitis Recurrence? (2020) (0)
The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease (2015) (0)
Post‐traumatic Functional Mirror Movements in Klippel‐Feil Syndrome (2017) (0)
Deep-brain stimulation of the thalamic ventral intermediate nucleus in the management of Parkinson's disease (2016) (0)
Gaps and controversies in movement disorders: Introduction to the series (2017) (0)
Reply: Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: Need for long‐term clinical trials (2011) (0)
CHAPTER 10 – Toxic Movement Disorders: The Approach to the Patient with a Movement Disorder of Toxic Origin (2009) (0)
Lessons learned: neuroprotective trials in Parkinson's disease (2016) (0)
Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology‐Proven Cases (2023) (0)
Thanks to Editorial Board of Arquivos de Neuro-Psiquiatria (2021) (0)
Deep-brain stimulation of the globus pallidus internus in the management of Parkinson's disease (2016) (0)
Continuous, Subcutaneous Apomorphine Infusion for Persistent Motor Fluctuations in Parkinson’s Disease: Full results of the AP2-3000 open-label study (S32.008) (2023) (0)
Poverty and Slowness of Voluntary Movement (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alberto J. Espay?

Alberto J. Espay is affiliated with the following schools:

University of Cincinnati
Ruhr University Bochum
Rush University